About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Metabolic Mapping and Cardiac Resynchronization | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNANCT03420833

Metabolic Mapping and Cardiac Resynchronization

The purpose of this study is to gather information on the safety and effectiveness of cardiac resynchronization therapy (CRT) in patients who have mild heart failure (HF) and left bundle branch block ...

Lead sponsor: Yong-Mei Cha•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Yong-Mei Cha

Collaborators

National Heart, Lung, and Blood Institute (NHLBI)
Biotronik SE & Co. KG

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Left Ventricular Ejection Fraction (LVEF) 35%-50%
•New York Heart Association (NYHA) class I-II
•QRS duration of ≥120ms
•Left bundle branch block (LBBB)
•Patient is able to receive a transvenous pectoral CRT implant
•Patient is able to sign informed consent
•Two echocardiograms are required to confirm a stable reduced LVEF
•Patient is on optimal and stable medical therapy (ACE inhibitor or angiotensin II type 1 (AT1 )blocker, beta blocker, etc. over the last 6 months)

Exclusion Criteria

•Advanced comorbid conditions with life expectancy \<1 year
•Patient is \<18 of years of age
•Patient has a CRT device
•Female patients who is pregnant or not on a reliable form of birth control. Women of childbearing potential are required to have negative pregnancy test within the 7 days prior to device implant
•Unwilling or unable to return for required follow-up visits
•Patient decides study participation is cost-prohibited

Related studies

MRI Assessment of Pulmonary Edema in Acute Heart Failure

NCT03999138 · Acute Heart Failure, Pulmonary Edema With Heart Failure

RECRUITINGPhase 2

CAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation

NCT06762964 · Fontan Circulation, Single Ventricle Heart Disease, and more

Biomarker Guided Discharge of Heart Failure Patients

NCT03103932 · Heart Failure; With Decompensation

Assessing Systemic Circulation and LV Performance in Adults

NCT04347655 · Heart Failure

RECRUITINGPhase 2

A Study of 68Ga-Fibroblast Activation Protein Inhibitor (FAPI) Positron Emission Tomography in Heart Failure

NCT07083011 · Heart Failure With Preserved Ejection Fraction

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 23, 2025Terms

Trial snapshot

StatusCOMPLETED

PhaseNA

Enrollment82

Start dateAug 2018

Last updatedJan 23, 2025

Condition

Locations shown

Mayo Clinic in Rochester

Rochester, Minnesota

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 23, 2025Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions